Thymosin Alpha 1 Boosts TB Treatment Success in Patients with Diabetes
Adding the immune peptide thymosin alpha 1 to standard TB chemotherapy significantly improved cure rates and immune function in diabetic TB patients after 12 months, with no additional side effects.
Quick Facts
What This Study Found
Adding thymosin alpha 1 (Tα1) to standard tuberculosis chemotherapy improved outcomes in patients who had both pulmonary TB and diabetes. At 6 months, there was no significant difference between groups. But at 12 months, the Tα1 group had significantly higher rates of sputum culture conversion (clearing the TB bacteria), chest lesion absorption, and lung cavity closure compared to chemotherapy alone (all P<0.05).
The Tα1 group also showed improved immune function: higher CD3+, CD4+, CD4+/CD8+ ratios, and NK cell levels compared to baseline and controls. Sputum cytokine levels shifted toward less inflammation — higher IL-2 and IFN-γ (pro-immunity), lower IL-4 and TNF-α (pro-inflammation). Adverse drug reactions did not differ between groups.
Key Numbers
n=120 · 60 per group · 12-month follow-up · Improved sputum conversion, lesion absorption, cavity closure (P<0.05 at 12 months) · Increased CD3+, CD4+, NK cells · No difference in adverse events
How They Did This
Randomized controlled trial at a single Chinese hospital. 120 patients with pulmonary TB complicated by diabetes were randomized to either thymosin alpha 1 plus standard multi-drug chemotherapy (n=60) or chemotherapy alone (n=60). Outcomes measured at 6 and 12 months included sputum culture conversion, chest lesion absorption, cavity closure, lymphocyte subsets (by flow cytometry), and sputum cytokines (by ELISA).
Why This Research Matters
Tuberculosis patients with diabetes have compromised immune systems and often respond poorly to standard TB treatment. Thymosin alpha 1 is an immune-modulating peptide that boosts T-cell function. This trial suggests it can help restore immune competence in these difficult-to-treat patients, improving cure rates without adding side effects — addressing a critical gap in TB management for diabetic patients.
The Bigger Picture
Diabetes is one of the biggest risk factors for TB worldwide, and the two diseases fuel each other — TB worsens blood sugar control while diabetes impairs the immune response needed to fight TB. As diabetes rates rise globally, especially in TB-endemic countries, treatments that can boost immunity in these patients become increasingly important. Thymosin alpha 1 is already approved in some countries for hepatitis B and as an immune adjuvant, so adding TB-diabetes to its indications would be a relatively straightforward regulatory path.
What This Study Doesn't Tell Us
Single-center study at one Chinese hospital, limiting generalizability. The abstract text appears to have a formatting error ("P0.05" likely should read "P<0.05"), making some statistical details unclear. Blinding is not mentioned, introducing potential bias. The 12-month timeframe may not capture long-term relapse rates. TB treatment outcomes in diabetic patients may differ across populations.
Questions This Raises
- ?Why did the benefit of thymosin alpha 1 only become apparent at 12 months and not at 6 months — is there a threshold of immune reconstitution needed?
- ?Would thymosin alpha 1 also benefit TB patients without diabetes, or is the benefit specific to immunocompromised populations?
- ?What is the optimal dosing schedule for thymosin alpha 1 in TB treatment — could shorter or more intensive courses achieve faster results?
Trust & Context
- Key Stat:
- Significant at 12 months Thymosin alpha 1 plus chemotherapy improved sputum conversion, lesion absorption, and cavity closure versus chemotherapy alone in diabetic TB patients
- Evidence Grade:
- This is a randomized controlled trial — a strong study design — but limited by being single-center, apparently unblinded, and conducted at one hospital. The 120-patient sample provides moderate evidence that warrants larger, multi-center confirmation.
- Study Age:
- Published in 2022 using data from 2017–2018. The findings remain relevant as the TB-diabetes comorbidity continues to grow globally and thymosin alpha 1 remains available in many countries.
- Original Title:
- Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes.
- Published In:
- Pakistan journal of medical sciences, 38(1), 179-184 (2022)
- Authors:
- Wu, Li, Luo, Pei-Pei, Tian, Yan-Hong, Chen, Lai-Yin, Zhang, Yan-Li
- Database ID:
- RPEP-06600
Evidence Hierarchy
Frequently Asked Questions
Why is TB harder to treat in people with diabetes?
Diabetes impairs the immune system — particularly T cells and other white blood cells needed to fight TB bacteria. This means diabetic TB patients often take longer to clear the infection, have higher relapse rates, and respond less well to standard antibiotic regimens.
What does thymosin alpha 1 do to the immune system?
Thymosin alpha 1 helps mature and activate T cells, NK cells, and other immune cells. In this study, it boosted CD3+ and CD4+ T cell counts and NK cells while shifting cytokine levels toward a more effective anti-TB immune response — essentially helping the immune system do its job better.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-06600APA
Wu, Li; Luo, Pei-Pei; Tian, Yan-Hong; Chen, Lai-Yin; Zhang, Yan-Li. (2022). Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes.. Pakistan journal of medical sciences, 38(1), 179-184. https://doi.org/10.12669/pjms.38.1.4419
MLA
Wu, Li, et al. "Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes.." Pakistan journal of medical sciences, 2022. https://doi.org/10.12669/pjms.38.1.4419
RethinkPeptides
RethinkPeptides Research Database. "Clinical efficacy of thymosin alpha 1 combined with multi-mo..." RPEP-06600. Retrieved from https://rethinkpeptides.com/research/wu-2022-clinical-efficacy-of-thymosin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.